Kanabo shares: should I buy after the IPO?

Medical cannabis is becoming popular right now and so are Kanabo shares. But I’m not buying the stock yet. Here’s why.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Kanabo (LSE: KNB) shares have been getting a lot of attention. Last week the firm listed on the London Stock Exchange through an initial public offering (IPO). Since then, the stock has created a lot of buzz in the investment community.

Normally I don’t consider IPOs, but this one is interesting. I’m not buying the shares for now, yet the stock is certainly on my radar. 

What’s the story behind Kanabo shares?

In a nutshell, Kanabo is an Israeli medical cannabis company. It listed on the UK stock market as part of a reverse takeover of Spinnaker Opportunities.

Kanabo’s unique selling point is that it has created VapePod, which is a medical grade vaporiser. The company’s goal is to sell this device, along with its cannabis cartridges, to consumers and promote the medicinal benefits of the drug. According to Kanabo, it’s selling initial products in Europe already, and is ready to scale up to meet market demands and projected sales and revenues.

At present, the company is also generating revenue by selling THC-free cannabidiol or CBD products to consumers. The short-term strategy is to sell these retail products while building out the Kanabo brand.

What’s all the hype about?

I’m bullish about the long-term prospects that legalised cannabis will have for medical use. Medical cannabis is being used to treat mental health conditions such as anxiety and depression. It’s also being used to treat insomnia and other sleep disorders.

Last year, the UK’s financial regulator, the Financial Conduct Authority (FCA) gave the green light to medical cannabis companies to list in London. Kanabo’s IPO comes amid a growing demand for the drug.

MGC Pharmaceuticals, another medical cannabis company IPO’d on the London stock market recently. But I reckon the IPO most investors are waiting for is Cellular Goods, which is expected to trade under the CBX symbol on February 26. This is London’s first listed ‘pureplay’ consumer CBD company. Even football star David Beckham has backed the company through his DB ventures firm.

Kanabo shares: would I buy?

While I’m bullish on medical cannabis, I’ll hold fire on buying Kanabo shares. There’s a lot of hype around the sector and the company. I reckon this buzz is over-inflating the share price.

Some investors are even calling Kanabo the ‘cannabis Nespresso’. I think this is overkill. For now I’ll monitor the stock and wait for the euphoria to die down.

The risks

There are risks involved with Kanabo shares. Firstly, I expect there to be a lot of competition in the sector. I think its VapePod product could take some time to bear fruit. Until then it’s relying on the sales of its retail CBD products. For now, I don’t think Kanabo has a proven edge over its competitors.

Let’s be frank, the company is still very small and loss-making. There’s a chance it may not be able to commercialise its medical cannabis products too. It’s also incurring research and development costs, which I’d expect to continue to impact its profitability.

I want to see the company deliver trading updates and results as a public company. That way, I have more information to make an informed investment decision on. So for now, I’ll sit on the fence and monitor the share price.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Nadia Yaqub has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »